 |
| Global Canine Atopic Dermatitis Treatment Drugs Market Size |
The global Canine Atopic Dermatitis Treatment Drugs Market is estimated to be
valued at US$ 1038.28 Mn in 2023 and
is expected to exhibit a CAGR of 16% over
the forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Canine atopic dermatitis is a chronic inflammatory skin disease caused by an
allergic reaction in dogs. Treatment drugs aim to reduce inflammation, itching
and skin lesions. Their growing adoption is helping pets and owners managing
symptoms of the condition effectively.
Market key trends:
Rising pet ownership and growing awareness about animal health management are
fueling demand for effective treatment options for canine atopic dermatitis.
According to recent statistics, over 85% of U.S. households own a pet. This has
led to significant R&D investments by key players to develop superior drugs
delivering desired results. For instance, anti-pruritic and targeted therapies
with minimal side effects are gaining popularity.
Segment
Analysis
The global canine atopic dermatitis treatment drugs market is segmented on the
basis of product type and distribution channel. By product type, the market is
segmented into antihistamines, corticosteroids, immune-modulators, biologics,
and others. The corticosteroids segment currently dominates the market due to
its effectiveness in treating acute atopic dermatitis in dogs. However, the
biologics segment is expected to witness fastest growth over the forecast
period owing to its targeted mechanism of action with fewer side effects.
Key Takeaways
Global
Canine Atopic Dermatitis Treatment Drugs Market Size is expected to
witness high growth, exhibiting CAGR of
16% over the forecast period, due to increasing pet ownership and rising
healthcare expenditure on pets.
Regional analysis
North America dominates the global market and is expected to maintain its
dominance over the forecast period. This is attributed to growing pet adoption
and high per capita animal healthcare expenditure in the region. Asia Pacific
region is expected to witness fastest growth owing to improving veterinary
infrastructure and increasing awareness about pet health in emerging countries
such as China and India.
Key players
Key players operating in the canine atopic dermatitis treatment drugs market
are Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences,
Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals
Plc, and Toray Industries, Inc. Zeotis Inc leads the market with its novel
topical therapeutic product. Elanco Animal Health Incorporated has strong
presence across markets due to its diversified product portfolio.
Get
More Insights On This Topic: https://www.pressreleasebulletin.com/canine-atopic-dermatitis-treatment-drugs-market/